Posted by Michael Wonder on 06 Oct 2021
EMA to consider rolling review for Merck's molnupiravir in coming days
5 October 2021 - The EMA will consider in the coming days whether to launch a rolling review of Merck's experimental COVID-19 pill, its head of vaccine strategy said on Tuesday
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, interim data showed last week.
